RxDoctor Payments Data

Mahvish Khan, MD

Psychiatry · Albuquerque, NMNPI 1174061899

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $611 and has fallen 75.7% since, to $149 in 2025. Among psychiatry clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,788in general payments, 2019–2025

Across 31 payments — averaging $57.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$372
  • Acadia Pharmaceuticals Inc$365
  • Teva Pharmaceuticals USA, Inc.$341
  • AstraZeneca$232
  • Johnson & Johnson$129
  • GSK$122
  • plus $227 from 6 others

What the payments were for

  • Food & beverage$1,788100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,788 in reported general payments places this provider in the 90th percentile of 174 psychiatry providers in New Mexico.

See all psychiatry providers in New Mexico

Medicare billing

Part B allowed, 2024
$20,305
Medicare patients
57
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Quetiapine Fumarate165$4,942
Bupropion XlBupropion Hcl89$4,625
Aripiprazole73$4,531
Prazosin Hcl94$3,637
Trazodone Hcl237$3,099
Atomoxetine Hcl22$2,676
Fluoxetine Hcl133$2,501
Gabapentin136$2,146
Duloxetine Hcl85$1,891
Hydroxyzine Hcl111$1,868
Clonazepam156$1,819
Olanzapine59$1,793
Venlafaxine Hcl ErVenlafaxine Hcl98$1,728
Lurasidone Hcl26$1,726
Divalproex Sodium46$1,680

Paid to pharmacies, not to this prescriber.

Other psychiatry in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →